logo
Scientists make surprising discovery about drinks stored in glass bottles: 'We were expecting the opposite result'

Scientists make surprising discovery about drinks stored in glass bottles: 'We were expecting the opposite result'

Yahoo17 hours ago

Researchers studying microplastic contamination in common beverages made a startling discovery: Drinks stored in glass bottles contained between five and 50 times the level of microplastics as drinks in plastic bottles.
"We were expecting the opposite result when we compared the level of microplastics in different drinks," said Iseline Chaïb of the Aquatic Food Safety Unit, which conducted the study at the ANSES Laboratory for Food Safety.
Researchers sought to investigate the levels of microplastics contained in a variety of popular drinks sold in France, as no microplastic study to date had investigated the French beverage market.
"The aim of the ANSES study was to determine the level of microplastic contamination in drinks such as water, soda, iced tea, wine, and beer," according to ANSES. "It also sought to establish the impact of their containers on this level."
The results shocked even the researchers themselves.
"It was observed that the most contaminated containers were glass bottles," the study found. "Caps were suspected to be the main source of contamination, as the majority of the particles in isolated beverages were identical to the color of the caps and shared the composition of the outer paint."
Consistent with this hypothesis, wine held in bottles topped with corks showed little sign of microplastic contamination, per ANSES.
"On average, in glass bottles of cola, lemonade, iced tea, and beer, there were around 100 microplastic particles per liter," ANSES said. "This number was five to 50 times lower in plastic bottles and cans."
The study showed that we cannot simply rely on our intuition or common sense when it comes to protecting ourselves and our families from microplastic contamination.
It also demonstrated the troubling extent to which microplastics have permeated our environment, our food supply, our drinking water, and even our bodies.
When you think about a product's packaging, which of these factors is more important to you?
The way it looks
The information it provides
The waste it produces
I don't think about packaging at all
Click your choice to see results and speak your mind.
While the full health risks of microplastic contamination are as yet unknown, we do know that microplastics enter the human body via ingestion, skin contact, and even inhalation.
"From food consumption alone, the intake of plastic particles in the human body ranges between 39,000 and 52,000 particles per person per year," according to the American Journal of Managed Care.
Once inside the body, microplastics enter the bloodstream and spread via the circulatory system. Microplastics have been detected, among other places, in the "liver, colon, lung, feces, placenta, and breast milk," per AJMC, with the highest concentrations found in the colon and liver.
Scientists studying the connection between microplastic contamination and certain medical conditions have found that people living in areas with higher levels of microplastic pollution also have a greater risk of diabetes, high blood pressure, and stroke, according to AJMC.
While advocates strive toward large-scale initiatives to limit plastic production and waste, there are steps we all can take in our own lives to limit the amount of plastic we use.
By finding fun, creative ways to repurpose and reuse plastic containers, we can prevent them from ending up in our landfills and waterways. Better yet, by avoiding single-use plastic containers in the first place, we can send a message to companies that we value more environmentally friendly packaging.
Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Burial Vault Sealed For 400 Years Found at End of Long-Forgotten Staircase
Burial Vault Sealed For 400 Years Found at End of Long-Forgotten Staircase

Yahoo

timean hour ago

  • Yahoo

Burial Vault Sealed For 400 Years Found at End of Long-Forgotten Staircase

After a disastrous 1970s renovation, archaeologists tasked with assessing decades of damage have stumbled upon unexpected layers of history in France's Saint-Philibert Church. The 12th-century church is the only structure in the city of Dijon built 'in the manner of the Romans'. It was decommissioned following the French revolution, and was used as a storehouse for salt in the mid-20th century, which wrought damage on the stone structure. As part of a misguided attempt to restore the church in 1974, a heated concrete slab was installed, which drew up further water and salt into the groaning structure, splitting stones apart. The concrete slab has since been removed, and in what started as a new restoration effort, archaeologists from the National Institute for Preventive Archaeological Research (INRAP) have found quite a trove. Beneath the slab, they found a long-forgotten staircase that led to a burial vault that's been sealed for at least 400 years. This is the final resting place of dozens of individuals, possible casualties of a catastrophic event like a pandemic or famine. Related: "In the transept, a vault, probably dating from the 15th to 16th centuries, has been identified," INRAP researchers state in a translated press release. "In it, the deceased, both children and adults, are buried in coffins, the bones of each individual being pushed to the sides to make room for the last deceased." The excavation has revealed further layers of history, including slab tombs from the 11th to 13th centuries and sarcophagi that date back to the 6th century. "Planned to extend to a depth of three meters, the excavation has revealed remains dating from Late Antiquity to the modern era," the team states. Confirmed: New Mexico Footprints Rewrite Timeline of Humans in America Video: How Far Away Would You Need to Be to Survive a Nuclear Blast? What Really Killed The Neanderthals? A Space Physicist Has a Radical Idea

AB Science provides an update on the renegotiation of loan repayment terms with its financial creditors
AB Science provides an update on the renegotiation of loan repayment terms with its financial creditors

Yahoo

timean hour ago

  • Yahoo

AB Science provides an update on the renegotiation of loan repayment terms with its financial creditors

PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE RENEGOTIATION OF LOAN REPAYMENT TERMS WITH ITS FINANCIAL CREDITORS AGREEMENT IN PRINCIPLE HAS BEEN REACHED ON A TWO-YEAR DEFERRAL OF REPAYMENT OF STATE-GUARANTEED LOANS SAVINGS OVER THE PERIOD WILL BE INVESTED IN R&D THIS AGREEMENT IS CONDITIONAL ON THE REPAYMENT DATE OF THE EIB COVID LOAN BEING POSTPONED, NEGOTIATIONS ON WHICH ARE CURRENTLY UNDERWAY. Paris, June 30, 2025, 8am CET AB Science SA (Euronext - FR0010557264 - AB) today announced that an agreement in principle has been reached with its financial creditors to postpone by 24 months the repayment of its bank debt (for a total amount of around 3.7 million euros at the opening of the conciliation procedure in January 2025). The implementation of this agreement is conditional on the postponement by at least 12 months of the repayment of a loan taken out with the EIB (for a total principal amount of 12 million euros, initially repayable in January and December 2028). Throughout the negotiation period, a standstill was granted by the creditors. The financial creditors unanimously agreed to the following restructuring terms : State-guaranteed loans (PGE) for a balance of 3.5 million euros Freeze on principal repayments from January 1, 2025 to December 31, 2026 Resumption of amortization on January 1th, 2027 Extension of the repayment period for the balance of 3.5 million euros, quarterly between March 31, 2027 and March 31, 2029 Innovation loan for a balance of 0.2 million euros Freeze on principal repayments from January 1, 2025 to September 30, 2025 Resumption of amortization on October 1st, 2025 Repayment of the balance of 0.2 million euros, quarterly between December 31, 2025 and June 30, 2026. The banks' agreement is conditional on the postponement by at least 12 months of the start of amortization of the EIB loan. The loan with the EIB is granted in two tranches of 6 million euros each, with the first tranche maturing on January 1, 2028 and the second on December 31, 2028. The Company is pursuing discussions with the EIB to obtain this postponement. About AB ScienceFounded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment. AB Science has developed a proprietary portfolio of molecules and the Company's lead compound, masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB). Further information is available on AB Science's website: Forward-looking Statements - AB ScienceThis press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance. These forward-looking statements can often be identified by the words "expect", "anticipate", "believe", "intend", "estimate" or "plan" as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents published by AB Science. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations. For additional information, please contact: AB ScienceFinancial Communication & Media Relations investors@ Attachment Standstill Banques VEng VFError in retrieving data Sign in to access your portfolio Error in retrieving data

AB Science provides an update on the renegotiation of loan repayment terms with its financial creditors
AB Science provides an update on the renegotiation of loan repayment terms with its financial creditors

Associated Press

timean hour ago

  • Associated Press

AB Science provides an update on the renegotiation of loan repayment terms with its financial creditors

PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE RENEGOTIATION OF LOAN REPAYMENT TERMS WITH ITS FINANCIAL CREDITORS AGREEMENT IN PRINCIPLE HAS BEEN REACHED ON A TWO-YEAR DEFERRAL OF REPAYMENT OF STATE-GUARANTEED LOANS SAVINGS OVER THE PERIOD WILL BE INVESTED IN R&D THIS AGREEMENT IS CONDITIONAL ON THE REPAYMENT DATE OF THE EIB COVID LOAN BEING POSTPONED, NEGOTIATIONS ON WHICH ARE CURRENTLY UNDERWAY. Paris, June 30, 2025, 8am CET AB Science SA (Euronext - FR0010557264 - AB) today announced that an agreement in principle has been reached with its financial creditors to postpone by 24 months the repayment of its bank debt (for a total amount of around 3.7 million euros at the opening of the conciliation procedure in January 2025). The implementation of this agreement is conditional on the postponement by at least 12 months of the repayment of a loan taken out with the EIB (for a total principal amount of 12 million euros, initially repayable in January and December 2028). Throughout the negotiation period, a standstill was granted by the creditors. The financial creditors unanimously agreed to the following restructuring terms : State-guaranteed loans (PGE) for a balance of 3.5 million euros Freeze on principal repayments from January 1, 2025 to December 31, 2026 Resumption of amortization on January 1th, 2027 Extension of the repayment period for the balance of 3.5 million euros, quarterly between March 31, 2027 and March 31, 2029 Innovation loan for a balance of 0.2 million euros Freeze on principal repayments from January 1, 2025 to September 30, 2025 Resumption of amortization on October 1st, 2025 Repayment of the balance of 0.2 million euros, quarterly between December 31, 2025 and June 30, 2026. The banks' agreement is conditional on the postponement by at least 12 months of the start of amortization of the EIB loan. The loan with the EIB is granted in two tranches of 6 million euros each, with the first tranche maturing on January 1, 2028 and the second on December 31, 2028. The Company is pursuing discussions with the EIB to obtain this postponement. About AB Science Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment. AB Science has developed a proprietary portfolio of molecules and the Company's lead compound, masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB). Further information is available on AB Science's website: . Forward-looking Statements - AB Science This press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance. These forward-looking statements can often be identified by the words 'expect', 'anticipate', 'believe', 'intend', 'estimate' or 'plan' as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents published by AB Science. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations. For additional information, please contact: AB Science Financial Communication & Media Relations [email protected] Attachment Standstill Banques VEng VF

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store